

Variant: *NM_000314.8(PTEN):c.64G>T (p.Asp22Tyr)*

Version: 1.0

CA377782011 [↗](#)

468706 (ClinVar) [↗](#)

Gene: PTEN ([HGNC:5728](#))

Condition: PTEN hamartoma tumor syndrome ([MONDO:0017623](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: 367476c0-29fd-418a-be77-1340085d066d

Approved on: 2026/6/16

Published on: 2026/6/26

HGVS expressions

NM_000314.8:c.64G>T

NM_000314.8(PTEN):c.64G>T (p.Asp22Tyr)

NC_000010.11:g.87864533G>T

CM000672.2:g.87864533G>T

NC_000010.10:g.89624290G>T

CM000672.1:g.89624290G>T

NC_000010.9:g.89614270G>T

NG_007466.2:g.6095G>T

NG_033079.1:g.3905C>A

ENST00000700029.2:c.64G>T

ENST00000710265.1:c.64G>T

ENST00000472832.3:c.64G>T

ENST00000688922.2:c.64G>T

ENST00000700021.1:c.64G>T

ENST00000700022.1:c.64G>T

ENST00000706954.1:c.64G>T

ENST00000706955.1:c.64G>T

ENST00000686459.1:c.64G>T

ENST00000688158.1:c.64G>T

ENST00000688308.1:c.64G>T

ENST00000693560.1:c.583G>T

ENST00000371953.8:c.64G>T

ENST00000371953.7:c.64G>T

ENST00000462694.1:n.66G>T

ENST00000487939.1:n.85G>T

ENST00000610634.1:c.-39G>T

ENST00000618586.1:n.33G>T

NM_000314.5:c.64G>T

NM_000314.6:c.64G>T

NM_001304717.2:c.583G>T

NM_001304718.1:c.-642G>T

NM_000314.7:c.64G>T

NM_001304717.5:c.583G>T

NM_001304718.2:c.-642G>T

Likely Pathogenic

Met criteria codes 5

PM5

PS2

PP2

PP3

PM2_Supporting

Evidence Links 0

Expert Panel

PTEN VCEP

Criteria Specification Information

Criteria Specification: ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for PTEN Version 3.2.0

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

PTEN VCEP

PTEN c.64G>T (p.Asp22Tyr) meets criteria to be classified as Likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.2.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS2: De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor SCV003923984.2). PM5: Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 233456, SCV004183305.1). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PP3: REVEL score > 0.7 (score of this variant = 0.957) PM2_supporting: Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).

Met criteria codes

PM5	i ✓	Missense change at an amino acid residue where a different missense change determined to be pathogenic or likely pathogenic and with equal or lesser BLOSUM62 score has been seen before (ClinVar Variation ID 233456, SCV004183305.1).
PS2	i ✓	De novo (both maternity and paternity confirmed) observation in a patient with the disease and no family history. (internal laboratory contributor SCV003923984.2).
PP2	i ✓	PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
PP3	i ✓	REVEL score > 0.7 (score of this variant = 0.957)
PM2_Supporting	i ✓	Absent in large sequenced populations OR present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).

Curation History



▼

▼

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.